

# Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

NCT06672016

---

|            |                           |
|------------|---------------------------|
| Status     | RECRUITING                |
| Phase      | Phase 3                   |
| Sponsor    | Mylan Pharmaceuticals Inc |
| Enrollment | 1,500 participants        |

## Key Eligibility Criteria

---

### Inclusion (7)

- Healthy, post-menarcheal and premenopausal women at risk of pregnancy who are at least 16 years of age.
- Desires to avoid pregnancy, is seeking to use hormonal contraception for at least 1 year.
- Has negative UPT results at screening and at enrollment visits.
- Has normal, regular menstrual cycles that are between 21 and 35 days in duration over the last 6 months.
- Engages in regular heterosexual vaginal intercourse (at least once per cycle), with a partner who is not known to be sub fertile or infertile.

... and 2 more (see full listing online)

### Exclusion (20)

- Known or suspected pregnancy or planning pregnancy during next 12 months.
- Participants with known hypersensitivity or intolerance to progestins, or any components of the progestin patch.
- History or presence of dermal sensitivity to medicated patches or to topical applications including bandages, surgical tape.
- Known infertility (current or known history) or history of sterilization in either partner.
- Received injectable hormonal contraceptive therapy within 10 months of study enrollment.

... and 15 more (see full listing online)

## Locations (57 total)

---

Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States  
SEC Clinical Research, Dothan, Alabama, United States  
AMR Mobile, Mobile, Alabama, United States  
... and 54 more locations